Blunt Fascial vs. Veress Needle Entry for Laparoscopic Surgery
(BluntFascial Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial compares two techniques for initiating laparoscopic surgery, a minimally invasive procedure. The researchers aim to determine if using a blunt instrument for entry (blunt fascial abdominal entry) is as effective as using a Veress needle (Veress needle abdominal entry), focusing on the time to start the surgery and patient recovery. Individuals undergoing regular laparoscopic surgery at Cedars-Sinai with a gynecologic surgeon may qualify. The trial will assess factors such as the speed of surgery initiation and postoperative pain levels. As an unphased trial, it offers patients the chance to contribute to advancements in surgical techniques that could enhance recovery experiences.
Do I need to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What prior data suggests that these peritoneal entry techniques are safe for laparoscopic surgery?
Research has shown that both the blunt fascial and Veress needle techniques are generally safe for surgeries. Studies indicate that complications with the blunt fascial entry are rare, occurring in about 1.1 to 5.5 out of every 1000 procedures, with very few people experiencing problems. These studies reported no major injuries, such as damage to blood vessels or gas leaks.
For the Veress needle technique, the risk of injury is slightly higher but remains low, with research suggesting injuries occur in about 2 to 3 out of every 1000 procedures.
Overall, while both techniques carry some risks, most patients tolerate them well.12345Why are researchers excited about this trial?
Researchers are excited about this trial comparing the blunt fascial entry and Veress needle entry techniques for laparoscopic surgery because it could lead to safer, more efficient surgical procedures. The blunt fascial entry method may reduce the risk of injury to internal organs and blood vessels, a concern with the traditional Veress needle technique. Additionally, the blunt approach could potentially offer quicker recovery times and less postoperative pain for patients. Understanding these differences could improve surgical outcomes and refine best practices in minimal access surgery.
What evidence suggests that this trial's entry techniques could be effective for laparoscopic surgery?
This trial will compare the blunt fascial entry technique with the Veress needle entry technique for laparoscopic surgery. Research has shown that both techniques are generally safe. Participants in the blunt fascial entry arm will experience a method known for consistency and a lower risk of injury compared to non-visual methods, with complication rates between 1.1 and 5.5 per 1000 cases. Participants in the Veress needle entry arm will undergo a technique with about an 89% success rate on the first attempt and a low injury rate of around 0.23% to 0.31%. Both methods are considered equally safe and effective, each offering distinct benefits in ease of use and risk of complications.13567
Who Is on the Research Team?
Raanan Meyer, MD
Principal Investigator
Cedars-Sinai Medical Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 who are having laparoscopic surgery at Cedars-Sinai Medical Center with a Minimally Invasive Gynecologic Surgery division surgeon. Participants must consent to the study's procedures and be available throughout its duration.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo laparoscopic gynecologic surgery using either the blunt fascial or Veress needle peritoneal entry technique
Follow-up
Participants are monitored for postoperative complications and pain scores
What Are the Treatments Tested in This Trial?
Interventions
- Blunt fascial abdominal entry
- Veress needle abdominal entry
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cedars-Sinai Medical Center
Lead Sponsor